PTVE250117C5000
- 0.00
- 0.000.00%
Pactiv Evergreen Newsroom
RBC Capital Downgrades Pactiv Evergreen(PTVE.US) to Hold Rating, Raises Target Price to $18
RBC Downgrades Pactiv Evergreen to Sector Perform From Outperform, Raises Price Target to $18 From $14
Jefferies Downgrades Pactiv Evergreen(PTVE.US) to Hold Rating, Raises Target Price to $18
Express News | Pactiv Evergreen Inc : Jefferies Cuts to Hold From Buy; Raises Target Price to $18 From $15
Walgreens Boots Alliance, Alaska Air And RH Are Among Top Mid-Cap Gainers Last Week (December 9-13): Are The Others In Your Portfolio?
Key Deals for the Week: Patterson, Hershey & Mondelez, AIG & Nippon and More
Amazon To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday
This Pinterest Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Pactiv Evergreen Analyst Ratings
Baird Maintains Pactiv Evergreen(PTVE.US) With Hold Rating, Raises Target Price to $18
Express News | Pactiv Evergreen Inc : Citigroup Cuts to Neutral From Buy
Novolex to Merge With Pactiv Evergreen in $6.7bn Deal
Citi Downgrades Pactiv Evergreen(PTVE.US) to Hold Rating, Raises Target Price to $18
Sector Update: Financial Stocks Decline Monday Afternoon
Apollo-Backed Novolex to Buy Pactiv Evergreen for $3.22 Billion - Update
Pactiv Evergreen Shares Are Trading Higher After the Company Announced It Will Merge With Novolex in Which Pactiv Shareholders Will Receive $18.00 per Share in Cash.
Top Midday Stories: China Probing Nvidia Over Potential Anti-Monopoly Law Breaches; Gallagher to Acquire AssuredPartners for $13.45 Billion
Pactive Evergreen's Stock Surges on Novolex Buyout Offer
Trading Halt: Halt Status Updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times
Apollo's Novolex to Buy Pactiv Evergreen for $18 a Share